Expanding the RLT Target Landscape: From Novel Target Selection to Candidate Optimization

• Explore the rationale for selecting novel targets with therapeutic potential beyond established RLT targets
• Apply lessons learned from advancing PSMA and FAP programs into clinical development to inform target selection and candidate optimization
• Leverage insights from PSMA and FAP around affinity, internalization, tumor uptake and retention to guide the design of next-generation candidates

Speakers:

Keene Wei

Chief Executive Officer

Vitsgen Therapeutics, Inc.